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Abstract
Background: Seventy percent of urban populations in sub-Saharan Africa live in slums. Sustaining HIV patients in these
high-risk and highly mobile settings is a major future challenge. This study seeks to assess program retention and to find
determinants for low adherence to antiretroviral treatment (ART) and drop-out from an established HIV/ART program in
Kibera, Nairobi, one of Africa’s largest informal urban settlements.
Methods and Findings: A prospective open cohort study of 800 patients was performed at the African Medical Research
Foundation (AMREF) clinic in the Kibera slum. Adherence to ART and drop-out from the ART program were independent
outcomes. Two different adherence measures were used: (1) ‘‘dose adherence’’ (the proportion of a prescribed dose taken
over the past 4 days) and (2) ‘‘adherence index’’ (based on three adherence questions covering dosing, timing and special
instructions). Drop-out from the program was calculated based on clinic appointment dates and number of prescribed
doses, and a patient was defined as being lost to follow-up if over 90 days had expired since the last prescribed dose. More
than one third of patients were non-adherent when all three aspects of adherence – dosing, timing and special instructions
– were taken into account. Multivariate logistic regression revealed that not disclosing HIV status, having a low level of
education, living below the poverty limit (US$ 2/day) and not having a treatment buddy were significant predictors for non-
adherence. Additionally, one quarter of patients dropped out for more than 90 days after the last prescribed ART dose. Not
having a treatment buddy was associated with increased risk for drop-out (hazard ratio 1.4, 95% CI=1.0–1.9).
Conclusion: These findings point to the dilemma of trying to sustain a growing number of people on life-long ART in
conditions where prevailing stigma, poverty and food shortages threatens the long-term success of HIV treatment.
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Introduction
Sustaining life-long antiretroviral treatment (ART) in the
rapidly growing urban slums of sub-Saharan Africa, where 70%
of urban populations live, is a major future challenge [1]. Urban
slums are poorly supplied with basic services for health, education,
sewage systems, water and electricity [1]. In combination with
high unemployment, sexual risk behavior, overcrowding and
insecurity, urban slums have worse health indicators than rural
areas including higher rates of alcohol consumption, smoking,
drug use and communicable diseases such as HIV [2,3]. Health
planning in the slums is a major challenge due to high mobility,
especially since there is very little information about the burden of
disease in the slums due to insufficient registration [4].
Adherence to ART is crucial for treatment success among HIV
patients [5,6,7,8]. High levels of adherence is a prerequisite for
maintained viral suppression [9,10] and a lower risk of drug
resistance [11,12] in turn preventing premature morbidity and
mortality [5,13]. Low adherence is the second strongest determi-
nant for disease deterioration and death after CD4 count [14].
Non-adherence to ART is a substantial challenge in resource-poor
settings like urban slums, where increasing drug resistance is hard
to combat using the limited treatment alternatives available.
The number of patients discontinuing, or dropping out of ART
in sub-Saharan Africa is believed to be substantial [15,16]. Rosen
et al (2007) found that, on average, 40% of patients enrolled in
sub-Saharan African ART programs had discontinued their
treatment after two years [17].
Nairobi, Kenya, has roughly 100 urban slums and, according to
UN-Habitat estimates, about half of Nairobi’s three million
inhabitants live in slums. Kibera, one of Africa’s largest urban
slums, is situated in the heart of Nairobi and estimated to have a
population of between 600 000 and 2 million, depending on the
season. Specific adherence studies in urban slums are few but our
group concluded in a retrospective study that 27% of patients
attending the African Medical and Research Foundation (AM-
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and that 29% discontinued the ART program [18]. The
probability of remaining in the program was 0.65 after 2 years
[18].
As more patients are initiated on life-long ART, one of the
major future challenges, apart from securing sustainable funding,
lies in retaining patients in care and in sustaining adherence to
ART [19]. Much has already been done to achieve an
understanding of the barriers and facilitators to ART adherence
[17,20,21] but context-specific knowledge regarding urban slums
is lacking [20,22]. The objective of this study was to find
determinants for low adherence to ART and program drop-out
in a resource-poor, urban, sub-Saharan African setting.
Methods
Setting and population
Kenya has 38.3 million inhabitants and 1.6–1.9 million HIV-
infected patients. At the end of 2008, WHO, UNAIDS and
UNICEF estimated that approximately 44% of the people in need
were receiving ART in sub-Saharan Africa. In Kenya, 308 000
adults were receiving ART at the end of 2009, corresponding to a
coverage of 70.4% of those in need having been initiated on ART.
This study was conducted at the AMREF clinic in the Kibera
slum, Nairobi, Kenya. Most people in Kibera live in small houses
made of mud and corrugated metal with almost no access to
electricity or sewerage. The majority lives off petty trade or casual,
day-to-day labor. The slum houses people of about 40 different
ethnic backgrounds from all over Kenya. The population is
constantly changing since people are highly mobile. A vast number
of health care providers, both national and international, offer
different services for Kibera inhabitants but there is no, or very
little, coordination between these providers. The AMREF clinic in
Kibera offers preventive, diagnostic and basic health care, as well
as care services for women and children. One medical officer, 3
clinical officers, 14 nurses, 2 nutritionists, 2 pharmacists and 8
community health care workers run the clinic. As the first ART
provider in Kibera, the centre has offered free treatment for
opportunistic infections and ART care and support to HIV-
infected Kibera residents since February 2003. A treatment buddy
(i.e. a friend or family member, known to the clinic, helping the
patient taking ART) is not requested but patients are advised to
have one. A nutrition program provides fortified flour to HIV-
infected adults and patients with TB if they have a body mass
index below 18.4, and to all HIV-infected children.
ART regimens
Patients who present with WHO clinical stage 3 or 4, or, with a
CD4-count of ,250 cells/mm
3 are eligible for ART at the
AMREF clinic, according to Ministry of Health guidelines.
Patients’ CD4 cells, clinical status and, when there are signs of
treatment failure, viral load are routinely monitored by the
AMREF staff. Under normal conditions, patients collect their
ART from the AMREF pharmacy every 30 days. First-line ART-
regimes at the AMREF clinic include stavudine, lamivudine, and
nevirapine/efavirez. Second-line regimes include zidovudine,
abacavir, didanosine, ritonavir-boosted lopinavir (Kaletra) and
tenofovir. By March 2010, the AMREF clinic in the Kibera slum
had initiated 1 792 patients on ART.
Data collection and study design
A prospective open cohort study was conducted. All consecutive
patients, HIV-positive, $18 years of age, visiting the clinic during
the study period (9 September, 2007–20 March 2010) and either
on ART or in the process of starting ART were eligible for the
study. Local clinical officers (CO) and a research assistant at the
clinic were trained by the first author (CU) before study initiation.
The COs, in collaboration with the attendant in charge, identified
patients eligible for the study. One research assistant (AL)
performed all baseline interviews with those patients who gave
their informed consent to participate after double-checking their
eligibility.
The baseline and follow-up questionnaires were developed in
close collaboration with the AMREF staff, piloted on two
occasions and adjusted several times after feedback from staff at
the clinic with different professional backgrounds. The question-
naires were based on a modified Adult Aids Clinical Trials Group
adherence questionnaire, (AACTG questionnaire) [23].
The baseline questionnaire consisted of 68 closed questions
covering the following socio-demographic factors: age, gender,
ethnicity, religion, civil status, number of children, level of
education, income, work status, living arrangements and alco-
hol/drug consumption. The patients were also asked about
disclosure of HIV status and social support. One question about
adherence to ART was asked: ‘‘When was the last time you missed
taking any of your medications? Within the past week/1–2 weeks
ago/2–4 weeks ago/1–3 months ago/more than 3 months ago/
never skip medication.’’ Finally, they were asked questions about
their reasons for not taking ART during the last month and
perceived side-effects. The same research assistant entered
baseline interview dates, out-patient number and the scheduled
date for a follow-up interview 6 months later, in both a logbook
and the patient’s medical file.
All patients, irrespective of treatment duration, were supposed
to have a shorter follow-up interview once every 6 months after
the baseline questionnaire. Since this was an open cohort
including patients who had recently started as well as those who
had longer experience of ART, we deemed that a follow-up time
of 6 months would allow for every patient to have passed the
initial challenging treatment period, and for those still in the
program to have gained some routine and experience of the
treatment. The follow-up questionnaire focused on self-reported
adherence to ART (as measured by a modified AACTG
questionnaire [23]). First, the patients were asked the names
and doses of each antiretroviral medicine (ARV) they were
taking. Drug samples were used to help patients identify their
drugs since most patients did not know them by name. Then,
patients were asked exactly how many pills they had failed to
take over the last four days. Further, patients were asked five
adherence questions: ‘‘During the past 4 days, on how many
days have you missed taking all your doses?’’; ‘‘Most anti-HIV
medications need to be taken on a schedule. How closely have
you followed your specific schedule over the last four days?’’;
‘‘Do your ARVs have special instructions?’’ followed by ‘‘If yes,
how often have you followed those special instructions over the
last four days?’’; ‘‘When was the last time you missed taking any
of your medications?’’ and ‘‘Did you miss any of your anti-HIV
medications last weekend?’’ (Appendix S1). Patients were finally
asked questions about their reasons for not taking ART during
the last month and perceived side-effects. The AACTG
questionnaire measures adherence during the last four days
and during the past weekend [23].
After the first descriptive analysis, the variables in the
questionnaires were categorized in different ways for easier
interpretation in the logistic models.
In addition to the questionnaires, the dates for clinic
appointments and number of prescribed ART doses were collected
from individual patient records at the clinic.
Long-Term Adherence to ART
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There is no consensus on what adherence measures to use [24].
Methods include indirect measures (e.g. pill counts, self-reports,
electronic monitoring devices and medication refill rates)
[10,25,26] and direct measures (e.g. observations, drug monitoring
and biological markers) [27]. Self-reported measures are quick and
inexpensive [28], have been shown to predict clinical outcome
[29] and have a significant association with viral load [28].
However, self-reports and pill counts tend to overestimate
adherence [29,30], while medication refill rates need electronic
pharmacy data systems in order to be efficient and are not
common in sub-Saharan Africa [31]. Adherence indices account
for different aspects of adherence [24]. Several other studies have
shown that not only dosing, but also the exact timing and
compliance with special instructions are important aspects of
adherence and impact on viral load [32,33]. Two separate
measures for adherence outcomes were used in this study: dose
adherence and an adherence index.
Dose adherence
Dose adherence was based on data from the follow-up interview
on number of doses per drug per day. The number of daily doses
was multiplied by four to get the prescribed number of doses over
the past four days and then divided by the self-reported number of
missed doses on each of the past four days in order to obtain the
proportion of prescribed dose actually taken over the past 4 days.
At least 95% of a prescribed dose over the last four days was
required to be classified as adherent.
Adherence index
The adherence index was based on questions from the follow-up
questionnaire covering dosing, timing and special instructions
(Table 1, Appendix S1). An adherence level of 95% was decided
for each item: i.e. at least 4/5 for timing, 5/5 for dosing and at
least 4/5 for special instructions was required to be classified as
adherent. Five out of five was required for dosing since the next
step (4/5) meant that patients had missed all doses on one out of
five days, i.e. 20% missed dose equal to only 80% adherence.
Patients were defined as adherent if they scored $13/15 points on
the adherence index (Table 1).
Drop-out from ART
Drop-out from ART was defined as the patient being without
ARVs for at least 90 days. By using routinely collected data from
patient records, the number of prescribed daily doses was added to
the last clinic appointment date. An additional 90 days were then
added to obtain the date when a patient was categorized as an
actual drop-out, assuming he or she had not returned before this
date. If classified as a drop-out, the date for the last clinic
appointment date was used as the drop-out date. A number of
patients categorized as drop-outs re-entered the program but kept
their classification as drop-outs in the analysis if they had been off
ART for more than 3 months, given the high likelihood of viral
rebound as well as the increased risk of drug resistance due to
suboptimal drug exposure. The patients that did not drop out were
censored on the last clinic appointment before the end of the
follow-up (20 March 2010).
Data analysis
Data was entered by the research assistant soon after the
performed interviews using the Microsoft Office Access data entry
program and exported to SPSS software version 18.0, (SPSS, Inc.,
Chicago, IL) for statistical analysis. Data was double checked for
validity by both the research assistant (AL) and the first author
(CU) on several occasions during the study period. Descriptive
statistics were collected on socio-demographic characteristics.
Mean and standard deviations were computed for numerical
variables and proportions for categorical variables. Following the
descriptive analysis, bivariate and multivariate logistic regression
models were applied to assess the association between patient
determinants and the outcome variables; i.e. (1) non-adherence,
defined as ,95% as measured by the dose adherence, (2) non-
adherence, defined as #13/15 points to the adherence index and
(3) drop-out from the program, defined as not returning more than
90 days after the last given dose of ART.
The association between the two adherence outcomes and
baseline data on sex, age, ethnic group, religion, education
(primary or secondary school), stable income (employed vs
unemployed/casual labour), living below the poverty limit (less
than 5 000 KSH/month, about 2 USD/day), number of people in
the household, number of biological children, number of other
Table 1. Adherence index: included variables, grading and score.
Adherence aspect
Covered The adherence index by Unge et al Grading Score
Timing/
Scheduling
‘Most anti-HIV medications need to be taken
on a schedule, such as ‘‘2 times a day’’ or
‘‘3 times a day’’ or ‘‘every 8 hours.’’ How
closely did you follow your specific
schedule over the last four days’
1 Never
2 Some of the time
3 About half of the time
4 Most of the time
5 All of the time
4/5
Quantification of adherence ‘During the past 4 days, on how many
days have you missed taking all
your doses?’
5 None
4 One day
3 Two days
2 Three days
1 Four days
5/5
Special
Instructions
‘How often did you follow those special
instructions over the last four days’
1 Never
2 Some of the time
3 About half of the time
4 Most of the time
5 All of the time
4/5
Maximum score:
Minimum score to be classified as adherent:
15
$13/15
doi:10.1371/journal.pone.0013613.t001
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Kibera, disclosed HIV status, having support taking medicines,
time to clinic and having been hospitalized since starting ART,
was assessed in bivariate analysis. Variables with a p,0.20 were
included in the multivariate logistic regression model and removed
using a backwards stepwise method (Wald’s test). A value of
p,0.05 was considered statistically significant in the final models.
Odds ratios (ORs) were always adjusted for age and sex regardless
of p-value. The final goodness of fit of the model was tested using
Hosmer-Lemeshow. A survival analysis (Cox regression model
with proportional hazard assumption tested with Shoenfeld
residuals) was also performed using the retrospective dataset, to
calculate the hazard ratios for the drop-out, their p-value and 95%
confidence intervals (CI). The survival analysis also included a
graphic presentation using a survival curve (time in days on the X
axis and survival cumulative function in Y axis) with ART
initiation as time zero and the event ‘‘not returning for more than
90 days after last given dose’’ as the loss to clinic appointment
date.
Ethical Standards
All the 800 ART clients who were asked to participate agreed to
be interviewed, following written informed consent. Ethical
approval was obtained from the Kenya Medical Research Institute
(KEMRI) and the Regional Ethical Review Board in Stockholm,
Sweden.
Results
Basic characteristics
Demographic data are shown in Table 2, 3, 4. A total of 800
patients (mean age 37 years, 66% females) were included in the
baseline assessment. The average household consisted of a widow
who resided with 2–3 people excluding herself, having 2–3
biological children and supporting 6 people, sometimes outside the
household. Seventy-five percent of the patients were living in
Kibera, two-thirds for more than 5 years. Less than half the
patients (49%) had known their HIV status for over 2 years but
most (83%) had disclosed to someone. The mean time on ART
was 23 (2–53) months. Only 40% of the respondents had a formal
treatment buddy while 50% had friends or family members
helping them to remember their medicines. A majority (60%) were
satisfied with the support they received from family and friends.
Thirty percent used alcohol, 8% consumed at least one unit of
alcohol per day, while the majority, 70%, said they never
consumed alcohol and only 0.6% admitted to ever using any
social drugs (heroin, marijuana, cocaine, khat or kuber).
Out of the 800 patients interviewed at baseline, 352 were
included in at least one follow-up interview. Patients were followed
up for a total period of 1 828 person-years.
Adherence outcomes
Resultsfromthe bivariateanalysisarepresentedinTable5and6.
Using dose adherence based on the number of missed doses
over the last four days, 11% (n=33) of the patients were non-
adherent (,95%) at six-month follow-up. The following variables
were significantly associated with non-adherence in bivariate
analysis: sex (female), undisclosed HIV status, not satisfied with
support in taking ART medicines, low level of education, living
below poverty limit (,US$ 2/day), short distance to clinic and
shorter average time on ART (non-adherent=14.4 months on
ARV; adherent=23.1 months on ARV). In the final multivariate
analysis, undisclosed HIV status (OR 4.70, 95% CI=1.78–12.43)
and living below the poverty limit (OR 3.28, 95% CI=1.27–8.48)
remained significantly associated with dose adherence ,95%,
adjusting for age and sex.
When asked to report long-term adherence, 37% of the 352
patients said they had missed at least one of their ARV doses at
some time between the past week and the last 3 months and as
Table 2. Characteristics of the ART patients included in the
cohort study (N=800).
Characteristics n (%) Missing
Sex 3
Males 274 (34.4)
Females 523 (65.6)
Mean age 6SD 37.268.6 3
Mean age by sex Males 40.6
Females 35.8
Mean time on ART6SD 23.0620.2 188
Ethnic group 3
Lou 251 (31.5)
Kisii 39 (4.9)
Kamba 163 (20.5)
Kikuyu 86 (10.8)
Maasai 3 (0.4)
Luhya 217 (27.2)
Nubien 12 (1.5)
Other 26 (3.3)
Religion 12
Protestant 476 (60.4)
Catholic 253 (32.1)
Muslim 23 (2.9)
Other 36 (4.6)
Highest education
achieved
12
Up to primary school 473 (60.0)
Secondary school/
higher
315 (39.4)
Present occupation 25
Non stable income 390 (50.3)
Stable income 385 (49.7)
Income/month 218
,5000 KSH 236 (40.5)
.5000 KSH 346 (59.5)
Relationship status 12
One partner 385 (48.9)
Two partners or more 26 (3.3)
Widow/widower 155 (19.7)
Single 119 (15.1)
Divorced/separated 103 (13.1)
Number of people
in household
12
0 92 (11.7)
1 97 (12.3)
2–3 274 (34.8)
.4 325 (41.2)
doi:10.1371/journal.pone.0013613.t002
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(Appendix S1). The most common reasons stated for missing drugs
over the past month were ‘‘simply forgot’’ (28%) and ‘‘ran out of
pills’’ (19%). Other reasons for missing drugs at baseline and
follow-up are summarized in Figure 1.
According to the adherence index based on dose, timing and
capacity to follow special drug instructions, 38% (130) patients
were classified as non-adherent (Figure 2). The following variables
were significantly associated with a low adherence index in
bivariate analyses: undisclosed HIV status, not satisfied with
support in taking ART, not having a treatment buddy, low level of
education and unstable income. The following variables remained
significantly associated with a low adherence index in the final
multivariate analysis: not having a treatment buddy (OR 1.60,
Table 3. Table 2 continued.
Characteristics n (%) Missing (n)
Number of children 12
0 75 (9.5)
1 131 (16.6)
2–3 338 (42.9)
.4 244 (30.9)
Number of people supporting financially 13
0 141 (17.9)
1 61 (7.8)
2–3 178 (22.6)
4–5 184 (23.4)
.6 223 (28.3)
Living in Kibera 12
No 201 (25.5)
Yes 587 (74.5)
Time living in Kibera 213
0–2 years 77 (13.1)
2–5 years 139 (23.7)
.5 years 371 (63.2)
Time to reach clinic from residence 12
Less than 10 minutes 74 (9.4)
10–30 minutes 431 (54.7)
31–60 minutes 174 (22.1)
More than one hour 109 (13.8)
Time since HIV diagnosis 12
,6 months ago 89 (11.3)
6–12 months ago 121 (15.4)
1–2 years ago 195 (24.7)
over 2 years ago 383 (48.6)
Disclosed status to anyone 12
Yes 653 (82.9)
No 135 (17.1)
Initial ART provider 190
AMREF 535 (87.7)
MSF 7 (1.1)
Private vendor 13 (2.1)
Other 55 (9.0)
Have a treatment buddy 12
Yes 315 (40.0)
No 473 (60.0)
Satisfied with support from friends/family 12
Yes 472 (59.9)
No 316 (40.1)
doi:10.1371/journal.pone.0013613.t003
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CI=1.21–3.15) also adjusted for age and sex.
Drop-out from program
Of the 800 patients on ART included in the baseline
assessment, 101 patients were excluded from the survival analysis
due to missing data on appointment dates and number of doses
prescribed. Of the 699 patients included in the analysis, 163 (23%)
dropped out for more than 90 days after the last prescribed dose,
leaving 536 (77%) in the ART program at the end of the study.
The total number of clinic appointment years of follow-up was 1
828. The Cox regression model showed a significantly higher
hazard ratio for people not having a treatment buddy (HR 1.41,
95% CI=1.02–1.94), adjusted for age and sex (Figure 3).
Missing data
Data on clinic appointment dates and number of prescribed
doses were missing for 101 patients mainly due to inconsistencies
in outpatient numbers and/or clinic appointment dates. Further,
information on what happened to the drop-outs was not available
although efforts were made to trace these drop-outs with the help
of community health workers. A few variables included in the
statistical modelling (time in Kibera, time since ART initiation,
income level, having had another previous ART provider or being
hospitalized due to AIDS) had a substantial amount of missing
values (Table 2) and further analyses were therefore performed to
assess the potential of non-random bias: The great majority, 94%
(201/213), of those with missing data on time living in Kibera
were non-Kibera residents. Patients with missing data on time on
ART did not differ significantly in terms of gender, age or ethnicity
compared to other patients in the study, indicating a random
distribution of missing values. In this population time since HIV
diagnosis closely coincides with time since ART initiation to a
large extent making up for the missing values on time on ART.
Among those with missing information on income level (, or
.5000 Ksh), 91% (198/218) reported that they lacked a stable
and predictable income. Since AMREF was the first provider of
ART in Kibera it is unlikely that patients included in this long-
term follow-up would have been enrolled in another ART
program previous to our assessment. Lastly, any substantial degree
of hospitalization due to AIDS-related symptoms is unlikely in this
population given the lack of tertiary level care in Kibera. The
hypothesis that our data was missing completely at random
(MCAR) was also statistically verified using Little’s MCAR test (p-
value equal to 0.259) rejecting any systemic bias in terms of
missing data. In conclusion, the likelihood is low that the missing
values could have biased our results away from the null hypothesis.
Discussion
In this prospective cohort study of 800 HIV patients on ART in
the Kibera slum, Nairobi, Kenya, over a period of 2.5 years, more
than a third of patients were non-adherent taking dose, timing and
special instructions for ARVs into account. In addition, one in four
dropped out more than 90 days after their last prescribed ART
dose. Living below the poverty limit, having a low education and
lacking family support (non-disclosure or not having a formal
treatment buddy) were significant risk factors for non-adherence.
This raises urgent questions about the difficulties associated with
sustaining a growing number of individuals on life-long ART,
while actual investments in poverty and stigma reduction and in
schooling are seriously lagging behind in urban slums.
Eleven percent of the patients in this cohort were non-adherent
according to the dose adherence calculations based on the self-
reported number of pills missed during the last four days. These
findings are consistent with other studies in sub-Saharan Africa
[34]. In most adherence studies, the percentage of missed doses
during the last three or four days is usually the only aspect of
adherence being assessed [21]. Since many ART regimens
demand that patients take their pills at exact times, and that
some ART must be taken with food or on an empty stomach,
adherence is more than just taking the right number of pills per
day [32,33,35,36]. Therefore, an adherence index was created,
taking into account timing and special instructions, in addition to
dose adherence.
The fact that the proportion of patients classified as non-
adherent increased from 11% to 38% depending on the type of
adherence measure used (i.e. dose adherence versus adherence
index) indicates that patients often are classified as being adherent
when only the number of missed pills during the last few days are
assessed. Thus, it is important to view adherence as multi-factorial
and to assess different aspects including dose timing and capacity
to follow food restrictions, in order to achieve virologic suppression
[32,33]. However, the importance of following exact schedules
and food instructions is dependant on type of drug combination
and of special concern for patients on protease inhibitors (PIs) [37].
Although in the present cohort only 0.8% of the patients were on a
PI-based regimen, also some nucleoside reverse transcriptase
inhibitors (NRTIs) (e.g. didanosine) and non-nucleoside reverse
transcriptase inhibitors (NNRTIs) (e.g. efavirenz), both frequently
Table 4. Antiretroviral drugs used at last follow up, AMREF clinic (N=1770).
Antiretroviral drugs used at last
follow up ART n (%)
First line treatment
Stavudine 649 (36.7)
Lamivudine 1530 (97.6)
Nevirapine/Efvavirenz 1517 (85.7)
Second line treatment
Zidovudine 619 (35.0)
Didanosine 17 (1.0)
Lopinavir 42 (2.7)
Zidovudine 619 (35.0)
doi:10.1371/journal.pone.0013613.t004
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restrictions [38]. In this cohort, 38% of the patients had a low
adherence index score assessing timing and special instructions in
addition to dosing. This is in line with earlier studies from other
resource-poor African settings where 47–78% of patients are
categorized as adherent when dosing, timing and food instructions
are taken into account [32,34,35].
The most common reason for missing pills, simply forgetting to
take them, could be abridged through different intervention
strategies for reminding patients to take their HIV medication
such as electronic or telephone-based alarms and home visits
[39,40]. The second most common reason reported by patients
for not taking their drugs was ‘‘ran out of pills’’. The AMREF
clinic did not suffer from stock-outs of drugs which otherwise is a
serious barrier to high-quality ART programmes especially for
government providers in rural sub-Saharan Africa [41], but
patients coming late for drug refill was a frequent problem at the
clinic. The staff, also identified patients’ ignorance of the
importance of avoiding treatment interruption, refusal to come
for drug pick up, or travels up country to visit relatives without
Table 5. Bivariate analysis of background factors with respect to dose adherence and adherence index (N=352).
Dose adherent Adherent index
Adherent Non adherent Adherent Non adherent
n( % ) n( % ) n( % ) n( % )
Sex Females 163 (63.2) 27 (81.8) 140 65.4) 91 (70.0)
Males 95 (36.8) 6 (18.2) 74 (34.6) 39 (30.0)
Mean age6SD 37.568.3 37.467.2 37.968.5 37.068.2
Ethnic group Lou 88 (34.1) 8 (24.2) 73 (34.1) 38 (29.2)
Kisii 11 (4.3) 0 (0.0) 6 (2.8) 10 (7.7)
Kamba 50 (19.4) 6 (18.2) 52 (24.3) 22 (16.9)
Kikuyu 24 (9.3) 7 (21.2) 17 (7.9) 16 (12.3)
Maasai 1 (0.4) 0 (0.0) 1 (0.5) 0 (0.0)
Luhya 72 (27.9) 10 (30.3) 52 (24.3) 36 (27.7)
Nubien 5 (1.9) 1 (3.0) 5 (2.3) 2 (1.5)
Other 7 (2.7) 1 (3.0) 8 (3.7) 6 (4.6)
Religion Protestant 145 (57.5) 17 (51.5) 115 (55.3) 71 (55.9)
Catholic 79 (31.3) 11 (33.3) 70 (33.7) 40 (31.5)
Muslim 8 (3.2) 1 (3.0) 10 (4.8) 3 (2.4)
Other 20 (7.9) 4 (12.1) 13 (6.3) 13 (10.2)
Highest education Up to primary school 137 (54.4) 26 (78.8) 108 (51.9) 86 (67.7)
Secondary school/higher 115 (45.6) 7 (21.2) 100 (48.1) 41 (32.3)
Present occupation Non stable income 123 (49.4) 14 (42.4) 98 (47.8) 76 (59.8)
Stable income 126 (50.6) 19 (57.6) 107 (52.2) 51 (40.2)
Poverty ,5000 KSH/month 57 (30.3) 14 (58.3) 51 (32.5) 33 (37.1)
.5000 KSH/month 131 (69.7) 10 (41.7) 106 (67.5) 56 (62.9)
Marital status One partner 121 (48.0) 12 (36.4) 96 (46.2) 58 (45.7)
.One partner 6 (2.4) 2 (6.1) 5 (2.4) 6 (4.7)
Widow/widower 51 (20.2) 11 (33.3) 46 (22.1) 30 (23.6)
Single 36 (14.3) 5 (15.2) 31 (14.9) 17 (13.4)
Divorced/separated 38 (15.1) 3 (9.1) 30 (14.4) 16 (12.6)
People residing with 0 32 (12.7) 7 (21.2) 96 (46.2) 58 (45.7)
1 30 (11.9) 0 (0.0) 5 (2.4) 6 (4.7)
2–3 72 (28.6) 10 (30.3) 46 (22.1) 30 (23.6)
4–5 76 (30.2) 10 (30.3) 31 (14.9) 17 (13.4)
over 6 42 (16.7) 6 (18.2) 30 (14.4) 16 (12.6)
Number of children 0 22 (8.7) 1 (3.0) 16 (7.7) 9 (7.1)
1 43 (17.1) 4 (12.1) 36 (17.3) 18 (14.2)
2–3 109 (43.3) 18 (54.5) 89 (42.8) 55 (43.3)
4–5 53 (21.0) 6 (18.2) 45 (21.6) 28 (22.0)
6–7 19 (7.5) 2 (6.1) 18 (8.7) 11 (8.7)
over 8 6 (2.4) 2 (6.1) 4 (1.9) 6 (4.7)
doi:10.1371/journal.pone.0013613.t005
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of ARVs.
Following food instructions is especially difficult in resource-
poor settings where food insecurity is widespread. The fact that
about 25% of the patients in this cohort did not adhere to special
instructions (Figure 2), including food, could be interpreted from a
poverty perspective: 50% were unemployed or had unstable
incomes due to casual labor, 41% were classified as living in
absolute poverty. On top of this, an average Kibera citizen
financially supports 4–5 children and lives under dismal conditions
making it extremely difficult to follow special food instructions for
ART, as shown in a previous qualitative study in the same setting
[42], and indicated by other research [19,43,44].
Ensuring free access to ART and reducing transports costs are
often-mentioned initial interventions that promote adherence at
community and individual level [45,46], but for patients in the
Kibera slum, where ART is free of charge and people live at close
walking distance from clinics, stigma and lack of social support
have previously been shown to be more important barriers to
ART initiation [42]. Not disclosing HIV status and lack of a
formal treatment buddy were found to be significant, independent,
predictors for non-adherence in line with previous research
[20,34,45,47,48]. Although disclosure in order to attain social
support is desirable, stigma against people living with HIV is still
widespread according to a recent qualitative study performed by
our team in Kibera (unpublished results), and difficulties for
patients on ART to choose when and to whom they would like to
disclose, in an over-crowded context like the Kibera slum, is an
important reason for dropping out of ART [18,42].
Based on the clinic appointment dates and number of
prescribed doses, 163 (23%) of the patients dropped out of the
ART program for more than 90 days after the last prescribed dose.
In this study drop-out was used synonymously with loss to follow-
up (LTFU). Other studies from sub-Saharan Africa suggest that
much of LFTU is due to self-transfer between ART programs
[49,50,51]. Sustaining ART in urban slums is an increasing
challenge given the growing number of ART providers including
NGOs and bilateral donors, some of them competing openly for
HIV patients in Kibera with no coordinated referral between
programs. Several clinics for example provide food packages for
Table 6. Table 5 continued.
Dose adherent Adherent index
Adherent Non adherent Adherent Non adherent
n( % ) n( % ) n( % ) n( % )
People supporting financially 0 39 (15.5) 5 (15.2) 34 (16.3) 20 (15.7)
1 14 (5.6) 1 (3.0) 11 (5.3) 10 (7.9)
2–3 61 (24.2) 7 (21.2) 49 (23.6) 28 (22.0)
4–5 61 (24.2) 9 (27.3) 53 (25.5) 21 (16.5)
6–7 37 (14) 6 (18.2) 27 (13.0) 27 (21.3)
over 8 40 (15.9) 5 (15.2) 34 (16.3) 21 (16.5)
Living in Kibera 185 (73.4) 24 (72.7) 151 (72.6) 97 (76.4)
Time living in Kibera 0–2 years 20 (10.8) 3 (12.5) 14 (9.3) 11 (11.3)
2–5 years 35 (18.9) 5 (20.8) 33 (21.9) 15 (15.5)
over 5 years 130 (70.3) 16 (66.7) 104 (68.9) 71 (73.2)
Time to reach clinic Less than 10 minutes 12 (4.8) 4 (12.1) 10 (4.8) 9 (7.1)
10–30 minutes 146 (57.9) 17 (51.5) 122 (58.7) 68 (53.5)
31–60 minutes 62 (24.6) 9 (27.3) 49 (23.6) 37 (29.1)
More than one hour 32 (12.7) 3 (9.1) 27 (13.0) 13 (10.2)
Learned about HIV status ,6 months ago 28 (11.1) 9 (27.3) 22 (10.6) 16 (12.6)
6–12 months ago 31 (12.3) 6 (18.2) 26 (12.5) 15 (11.8)
1–2 years ago 67 (26.6) 5 (15.2) 50 (24.0) 33 (26.0)
over 2 years ago 126 (50.0) 22 (66.7) 188 (90.4) 105 (82.7)
Disclosed status to anyone 225 (89.3) 22 (66.7) 188 (90.4) 105 (82.7)
Got the ARV from in the beginning AMREF 222 (88.1) 31 (93.9) 183 (88.0) 102 (87.2)
MSF 4 (1.6) 0 (0.0) 4 (1.9) 0 (0.0)
Private vendor 2 (0.8) 0 (0.0) 0 (0.0) 1 (0.9)
Other 24 (9.5) 2 (6.1) 21 (10.1) 14 (12.0)
Been hospitalized after starting ARV 33 (13.1) 6 (18.2) 28 (13.5) 17 (14.5)
Have a treatment buddy 106 (42.1) 13 (39.4) 99 (47.6) 45 (35.4)
Satisfied with support from friends and family 165 (65.5) 21 (63.6) 135 (64.9) 80 (63.0)
Friends or family members help remember 130 (51.6) 13 (39.4) 113 (54.3) 56 (44.1)
Mean time on ARV6SD 23.1619.2 14.4612.7 23.5618.5 23.5621.1
doi:10.1371/journal.pone.0013613.t006
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doi:10.1371/journal.pone.0013613.g001
Figure 2. Different aspects of self-reported adherence at 6 months follow-up: 4-day recall dosing, timing, special instructions, and
adherence index including all three aspects. N=352.
doi:10.1371/journal.pone.0013613.g002
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provision of baby formula is one of the most attractive incentives
for young pregnant women living with HIV to self-transfer from
the AMREF clinic to other providers. In the present study data
were not available as to where the patients being classified as drop-
outs had gone but the clinic staff indicated that many probably
had self-transferred to nearby facilities that offered more benefits
such as food packages etc. Thus, although program loss is not
necessarily equal to treatment loss for the individual patient, it is
still associated with a considerable risk of at least temporary
treatment interruption. A Ugandan study found that 83% of
patients initially classified as LTFU could be traced to another
ART program [52], but the extent to which treatment
interruptions due to self-transfer or unguided program switch
had clinical or virological drawbacks was not studied. Underlying
individual circumstances for not having a treatment buddy (found
to be significantly associated with drop-out in our survival analysis)
are often strongly influenced by stigma and lack of social support,
all unlikely to change, at least in the short-term, regardless of ART
provider.
The strength of this study was that it was unique in its kind,
conducted in an urban slum, a very complex study area and home
to around one million highly mobile multi-ethnic people, living in
an area the size of Central Park in New York. In the very near
future most patients in need of ART in the world will live in
similar environments. Logistic challenges including security to
perform studies in this environment are enormous, yet interesting
findings were revealed in collaboration with the staff at the clinic.
The prospective study design enabled us to retrieve more accurate
follow-up information on adherence that could be linked to
baseline data, and also enabled the interviewer to validate patient
drop-outs directly with the staff while these patients were still fresh
in memory.
One limitation of the study was the amount of missing data,
caused by a number of issues, but following further analyses
judged to be random in nature. The fact that we studied
adherence among patients retained in care, but lacked adherence
data on patients LTFU, may have introduced a potential
systematic bias underestimating the true risk of low adherence
since patients that remain in the programme are more likely to be
adherent. Due to economic and logistical restraints, the
relationship between adherence outcomes and CD4 counts or
viral load was not possible to assess. The ,95% threshold used
for classification of non-adherence may have been too stringent.
This often cited measure comes from studies performed with
unboosted PIs [10], but later studies have shown that viral
suppression may be achieved with adherence levels of 50%–80%
based on NNRTIs [9].
Since 70% of urban populations in sub-Saharan Africa live in
slums, sustaining HIV patients on ART in these high-risk and
highly mobile settings is a major future challenge. The high
proportion of patients dropping out of treatment programs and
being non-adherent must be addressed using context-specific
solutions like extended counselling and community-based treat-
ment support. If policymakers and funders are serious about
making life-long ART available for patients in sub-Saharan
Africa, it is important to reduce competition between providers
and avoid the short-term funding strategies seen in this area. It is
equally important to invest in poverty reduction strategies and
education.
Figure 3. Survival function (days) for patients according to Treatment buddy.
doi:10.1371/journal.pone.0013613.g003
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